Table 2.
Qualitative assessment of SARS‐CoV‐2‐specific antibody avidity in serial serum samples from patients with COVID‐19
| Patient | Time since symptoms onset, d | Antibody reactivity | |||
|---|---|---|---|---|---|
| IgG | IgG after urea treatment | IgM | IgM after urea treatment | ||
| 1 | 27 | + | − | − | − |
| 39 | + | + | − | − | |
| 2 | 22 | + | − | − | − |
| 34 | + | − | − | − | |
| 3 | 25 | + | − | + | − |
| 35 | + | + | − | − | |
| 4 | 20 | + | + | − | − |
| 24 | + | + | − | − | |
| 5 | 10 | + | − | + | + |
| 16 | + | + | + | + | |
| 6 | 23 | + | − | + | − |
| 24 | + | − | + | − | |
| 7 | 30 | + | + | − | − |
| 31 | + | + | − | − | |
| 51 | + | + | − | − | |
| 59 | + | + | − | − | |
| 8 | 11 | + | − | − | − |
| 23 | + | + | − | − | |
| 9 | 30 | + | + | + | − |
| 40 | + | + | − | − | |
| 47 | + | + | − | − | |
| 10 | 7 | + | − | + | + |
| 15 | + | − | + | + | |
| 11 | 28 | + | + | + | − |
| 40 | + | + | + | − | |
| 12 | 21 | + | − | − | − |
| 26 | + | + | − | − | |
| 38 | + | + | − | − | |
| 13 | 21 | + | + | + | + |
| 48 | + | + | + | + | |
| 14 | 6 | + | − | − | − |
| 14 | + | − | − | − | |
| 15 | 14 | + | + | + | − |
| 18 | + | + | − | − | |
Abbreviations: COVID‐19, corona virus 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.